Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

0.38USD
15 Dec 2017
Change (% chg)

$0.01 (+2.94%)
Prev Close
$0.37
Open
$0.37
Day's High
$0.38
Day's Low
$0.35
Volume
124,595
Avg. Vol
94,107
52-wk High
$1.24
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial
Thursday, 7 Dec 2017 07:15am EST 

Dec 7 (Reuters) - Heat Biologics Inc ::SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL.HEAT BIOLOGICS - RECEIVED WRITTEN RESPONSES FROM U.S. FDA REGARDING HS-110 TRIAL DESIGN FOR TREATMENT OF NON-SMALL CELL LUNG CANCER.HEAT BIOLOGICS - FDA AGREED THAT TRIAL DESIGNS, BOTH SINGLE-ARM AND CONTROLLED, WOULD BE APPROPRIATE TO SUPPORT REGISTRATIONAL TRIAL OF HS-110.HEAT BIOLOGICS - TRIAL DESIGN DETAILS AND NEXT STEPS EXPECTED TO BE ANNOUNCED FOLLOWING READ-OUT OF PHASE 2 DATA, ANTICIPATED IN 2H 2018.  Full Article

Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​
Monday, 13 Nov 2017 07:12am EST 

Nov 13 (Reuters) - Heat Biologics Inc :Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​.Heat Biologics Inc - ‍cash and cash equivalents totaled approximately $4.3 million, as of September 30, 2017​.  Full Article

Heat Biologics Inc files for mixed shelf of up to $50 million ‍​
Monday, 30 Oct 2017 10:21am EDT 

Oct 30 (Reuters) - Heat Biologics Inc :Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​.  Full Article

SELEXIS SA AND PELICAN THERAPEUTICS SIGN AGREEMENT TO ADVANCE PELICAN’S IMMUNOTHERAPY CLINICAL PROGRAMS
Wednesday, 4 Oct 2017 08:00am EDT 

Oct 4 (Reuters) - Selexis SA::SELEXIS SA AND PELICAN THERAPEUTICS SIGN AGREEMENT TO ADVANCE PELICAN’S IMMUNOTHERAPY CLINICAL PROGRAMS.SELEXIS SA - CO, PELICAN THERAPEUTICS ENTERED INTO SERVICE AGREEMENT TO ADVANCE DEVELOPMENT OF PELICAN'S PROPRIETARY IMMUNOTHERAPY CLINICAL CANDIDATES.  Full Article

Heat Biologics says unit of co entered into a manufacturing agreement with KBI Biopharma
Wednesday, 27 Sep 2017 07:28am EDT 

Sept 27 (Reuters) - Heat Biologics Inc ::Heat Biologics Inc - on September 27, 2017, unit of co entered into a manufacturing agreement with KBI Biopharma -SEC filing.Heat Biologics- manufacturing agreement for cGMP production of its PTX-35 antibody and PTX-15 fusion protein.  Full Article

Heat Biologics been granted type C meeting with FDA
Tuesday, 12 Sep 2017 07:40am EDT 

Sept 12 (Reuters) - Heat Biologics Inc ::Heat Biologics- ‍been granted type C meeting with FDA; to discuss registrational pathway for non-small cell lung cancer trial with HS-110 in combination with Bristol Myers' opdivo.  Full Article

Heat Biologics says net loss for Q1 of 2017 was $3.2 million
Thursday, 11 May 2017 07:33am EDT 

May 11 (Reuters) - Heat Biologics Inc : :Says Net Loss for Q1 of 2017 was $3.2 million.Says Q1 loss per share $0.12.Q1 revenue $24,000.  Full Article

Sabby Healthcare Master Fund reports 9.7 pct passive stake in Heat Biologics
Monday, 17 Apr 2017 09:23pm EDT 

April 17 (Reuters) - Heat Biologics Inc ::Sabby Healthcare Master Fund Ltd. reports 9.70 percent passive stake in Heat Biologics Inc as on March 28, 2017 - sec filing.  Full Article

Heat Biologics management estimates cash of about $7.8 mln at Dec 31 2016
Thursday, 23 Mar 2017 08:01am EDT 

Heat Biologics Inc : Heat Biologics Inc- management estimates cash of approximately $7.8 million at December 31, 2016. .Heat Biologics - co's management preliminarily estimates for year ended Dec 31, 2016, co will report loss from continuing operations of about $13.0 million.  Full Article

Heat Biologics prices offering of 5,000,000 shares of common stock
Thursday, 23 Mar 2017 08:00am EDT 

Heat Biologics Inc : Says public offering of 5.00 million common shares priced at $0.80per share .Heat Biologics prices offering of 5,000,000 shares of common stock.  Full Article